Biopsy Guidance System Market Size, Share & Forecast Analysis to 2030

The global biopsy guidance system market size was valued at over USD 1 billion in 2025 and projected to grow at a significant CAGR of around 6% during the forecast period from 2026 to 2030. The market is witnessing steady growth due to the rising prevalence of cancer, increasing demand for minimally invasive diagnostic procedures, and advancements in image-guided biopsy technologies. Growing adoption of ultrasound, MRI, and CT-guided systems is improving biopsy accuracy and patient outcomes. The North America holds a significant market share due to advanced healthcare infrastructure and high adoption of precision diagnostic solutions.

Market Snapshot:

Key Insights:

• Rising cancer prevalence and increasing demand for minimally invasive diagnostics are driving global adoption of biopsy guidance systems.
• Breast biopsy dominates the application segment due to high cancer incidence, screening programs, and widespread image-guided biopsy adoption.
• Ultrasound-guided biopsy systems lead the product segment due to affordability, real-time imaging, and broad clinical applications.
• North America dominates the market with advanced healthcare infrastructure, high biopsy volumes, and strong technology adoption.

Key Factors Driving the Biopsy Guidance System Market Growth

The increasing prevalence of cancer and growing demand for early and accurate diagnosis are key factors driving the adoption of biopsy guidance systems worldwide. Rising cases of breast, lung, prostate, and other cancers are encouraging healthcare providers to utilize image-guided biopsy technologies that enable precise tissue sampling while minimizing procedural risks. The growing preference for minimally invasive diagnostic procedures, along with advancements in ultrasound-, CT-, and MRI-guided biopsy techniques, is further supporting market growth. Additionally, expanding healthcare infrastructure and increasing investments in advanced diagnostic imaging systems are improving access to biopsy guidance solutions across developed and emerging markets.

The increasing adoption of advanced image-guided biopsy technologies is further accelerating market expansion, as manufacturers focus on improving lesion targeting accuracy, visualization, and procedural workflow efficiency. In recent years, Hologic has expanded the adoption of its Affirm® Breast Biopsy Guidance System, which supports 2D and 3D breast biopsy procedures through integration with breast tomosynthesis technology, enabling improved lesion visualization, precise targeting, and enhanced workflow efficiency. Such advancements in stereotactic and tomosynthesis-guided biopsy platforms are strengthening the role of biopsy guidance systems in cancer diagnostics and contributing to their broader adoption across healthcare facilities.

Key Growth Drivers:

• Rising cancer incidence and demand for early diagnosis are increasing the adoption of image-guided biopsy systems for accurate tissue sampling and improved treatment planning.
• Growing preference for minimally invasive biopsy procedures is driving the use of ultrasound-, CT-, and MRI-guided systems that enhance precision while reducing procedural risks.
• Technological advancements in biopsy guidance platforms, including 3D tomosynthesis integration, improved imaging visualization, and workflow automation, are supporting higher adoption among healthcare providers.

Biopsy Guidance System Market Restraints

The high cost of biopsy guidance systems and associated imaging technologies is a major factor limiting market growth, particularly in developing and low-income regions. Advanced systems that integrate ultrasound, MRI, CT, or tomosynthesis guidance require significant capital investment, along with additional expenses for installation, maintenance, software upgrades, and specialized accessories. Limited healthcare budgets and uneven access to advanced diagnostic infrastructure can restrict the adoption of these systems in smaller hospitals and diagnostic centers.

The shortage of skilled professionals trained to operate advanced image-guided biopsy systems is another challenge affecting market expansion. These procedures require expertise in imaging interpretation, device handling, and precise targeting techniques, creating a dependency on specialized radiologists and clinicians. Additionally, regulatory complexities, reimbursement limitations, and concerns related to procedure-associated risks, such as bleeding, infection, or inaccurate sampling, may slow the adoption of biopsy guidance technologies in certain healthcare markets.

Growth Opportunities in the Global Biopsy Guidance System Market

The integration of artificial intelligence (AI), machine learning, and advanced imaging technologies presents significant opportunities for the biopsy guidance system market. AI-assisted image analysis, automated lesion detection, and real-time navigation capabilities can improve biopsy accuracy, reduce procedure time, and enhance clinical outcomes. As healthcare providers increasingly focus on precision medicine and personalized cancer care, demand is expected to grow for advanced biopsy guidance platforms that offer improved targeting and workflow optimization.

The expansion of healthcare infrastructure in emerging economies and increasing investments in diagnostic imaging technologies are creating new growth opportunities for market players. In 2023, the U.S. Food and Drug Administration (FDA) cleared the IGAR System developed by Insight Medbotics, an MRI-compatible robotic guidance platform designed to assist clinicians during breast biopsy and localization procedures. This regulatory milestone highlights the growing adoption of advanced robotic and image-guided technologies, creating opportunities for manufacturers to develop next-generation biopsy guidance solutions with enhanced precision and automation.

Key Growth Opportunities:

• AI-powered imaging integration creates opportunities for smarter biopsy guidance systems with enhanced lesion detection, accuracy, and procedural efficiency.
• Robotic-assisted and navigation-guided biopsy platforms offer growth potential through improved precision, minimally invasive procedures, and better clinical outcomes.
• Expanding healthcare infrastructure in emerging markets drives opportunities for wider adoption of advanced biopsy guidance technologies.

Industry Trends Shaping the Global Biopsy Guidance System Market

The biopsy guidance system market is increasingly shifting toward advanced image fusion, navigation-assisted, and minimally invasive biopsy technologies that improve targeting accuracy and clinical outcomes. Healthcare providers are adopting systems that combine MRI, ultrasound, and 3D visualization capabilities to enhance lesion localization and reduce sampling errors during complex biopsy procedures. The integration of automated navigation, real-time imaging, and software-assisted guidance is becoming a key trend as clinicians seek more precise and efficient diagnostic workflows.

A significant trend in the market is the growing adoption of MRI-ultrasound fusion and navigation-based biopsy platforms for prostate cancer diagnosis. In September 2025, the AmaKris Minimally Invasive Prostate Surgery Navigation System received an updated FDA clearance, supporting transperineal prostate biopsy procedures through real-time ultrasound guidance combined with MRI image fusion and 3D visualization of the prostate, biopsy needle, and planned puncture path. This development highlights the increasing adoption of advanced navigation technologies that enhance biopsy precision and support targeted tissue sampling.

Market Segments Insights:

By Product Type: The Ultrasound-guided Biopsy Systems Segment Dominated the Global Biopsy Guidance System Market

The global biopsy guidance system market is bifurcated into product type, application, end-user, and geography. On the basis of product type, the ultrasound-guided biopsy systems segment is expected to dominate the market due to their widespread clinical adoption, cost-effectiveness, and ability to provide real-time imaging during biopsy procedures. These systems are extensively used for breast, prostate, thyroid, liver, kidney, and soft tissue biopsies, enabling clinicians to accurately guide biopsy needles while minimizing patient discomfort and procedural complications. Their portability, absence of ionizing radiation, and suitability for both inpatient and outpatient settings further strengthen their market leadership.

The segment’s dominance is further supported by continuous product innovation and technological advancements. In November 2024, Mammotome launched the AutoCore™ Single Insertion Core Biopsy System, the first automated spring-loaded core needle device designed to simplify ultrasound-guided breast biopsy procedures through single-button operation, automated tissue collection, and improved workflow efficiency. Such innovations are accelerating the adoption of ultrasound-guided biopsy technologies by enhancing procedural precision, reducing procedure time, and improving the overall clinician and patient experience.

By Application: The Breast Biopsy Sub-category Holds the Largest Share of Global Biopsy Guidance System Market

On the basis of application, the global biopsy guidance system market is further segmented into breast biopsy, prostate biopsy, lung biopsy, liver biopsy, brain biopsy, kidney biopsy, and others. The breast biopsy segment dominated the market due to the rising global incidence of breast cancer and the widespread implementation of breast cancer screening programs. The increasing use of mammography, digital breast tomosynthesis, ultrasound, and MRI has significantly increased the demand for image-guided biopsy procedures that enable accurate lesion localization and minimally invasive tissue sampling. The availability of multiple image-guided biopsy modalities and continuous improvements in diagnostic imaging technologies further strengthen the segment’s leading market position.

The segment’s dominance is also reinforced by continuous product innovation from leading market players. In January 2026, BD (Becton, Dickinson and Company) received U.S. FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy platform designed to support procedures across different breast imaging modalities while improving procedural flexibility, visualization, and workflow efficiency. Such innovations are expected to accelerate the adoption of advanced image-guided breast biopsy technologies and reinforce the dominance of the breast biopsy segment in the global market.

The biopsy guidance system market research report presents the analysis of each segment from 2020 to 2030 considering 2025 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2026 to 2030.

Global Biopsy Guidance System Market Segmentation:

By Product Type:

• Stereotactic Guided Biopsy Systems
• Ultrasound-Guided Biopsy Systems
• MRI-Guided Biopsy Systems
• CT-Guided Biopsy Systems
• Others

By Application:

• Breast Biopsy
• Prostate Biopsy
• Lung Biopsy
• Liver Biopsy
• Brain Biopsy
• Kidney Biopsy
• Others

By End-User:

• Hospitals
• Diagnostic Imaging Centers
• Ambulatory Surgical Centers (ASCs)
• Specialty Clinics
• Others

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Regional Analysis: The North America Leading the Global Biopsy Guidance System Market

Geographically, the North America dominated the global biopsy guidance system market owing to its advanced healthcare infrastructure, high adoption of image-guided diagnostic technologies, and increasing prevalence of cancer. The region benefits from well-established breast, lung, and prostate cancer screening programs, a strong presence of leading medical device manufacturers, and favorable reimbursement policies for diagnostic imaging procedures. Continuous investments in precision medicine and minimally invasive diagnostics further support the widespread adoption of advanced biopsy guidance systems across hospitals and diagnostic centers.

The region’s leadership is further reinforced by the high volume of image-guided biopsy procedures performed annually. According to a U.S. population-based analysis published in the Journal of Women’s Health, approximately 1.59 million breast biopsies are performed annually in the United States, with ultrasound guidance used in nearly 87% of all breast biopsy procedures. This high procedural volume demonstrates the widespread adoption of image-guided biopsy technologies and continues to drive demand for advanced biopsy guidance systems across North America.

Competitive Analysis:

The biopsy guidance system market is moderately consolidated, with leading companies competing through product innovation, strategic partnerships, regulatory approvals, and geographic expansion to strengthen their market positions. Key players are focusing on integrating advanced imaging technologies, artificial intelligence, robotic-assisted navigation, and minimally invasive biopsy solutions to improve targeting accuracy, workflow efficiency, and clinical outcomes. Companies are also investing in research and development to expand their product portfolios across ultrasound-, MRI-, CT-, and stereotactic-guided biopsy applications.

Major market participants include Hologic, Inc., Becton, Dickinson and Company (BD), Mammotome, Siemens Healthineers AG, GE HealthCare, FUJIFILM Holdings Corporation, Canon Medical Systems Corporation, Cook Medical, Argon Medical Devices, Inc., and Merit Medical Systems, Inc. These companies continue to strengthen their competitive positions through new product launches, regulatory approvals, and technological advancements. Additionally, collaborations with hospitals, diagnostic imaging centers, and cancer care institutions, along with expansion into emerging markets, are enabling manufacturers to increase product adoption and enhance their global market presence.

Key Companies:

• Hologic, Inc.
• Becton, Dickinson and Company (BD)
• Mammotome
• Siemens Healthineers
• GE HealthCare
• FUJIFILM Holdings Corporation
• Canon Medical Systems Corporation
• Cook Medical
• Argon Medical Devices, Inc.
• Merit Medical Systems, Inc.
• Esaote S.p.A.
• Koninklijke Philips N.V.

Global Biopsy Guidance System Market Outlook

• Increasing adoption of AI-enabled imaging and navigation technologies will enhance biopsy accuracy, workflow efficiency, and clinical decision-making.
• Growing cancer screening initiatives and rising demand for minimally invasive diagnostics will continue driving biopsy guidance system adoption worldwide.
• Expansion of healthcare infrastructure in emerging economies will create new opportunities for advanced image-guided biopsy technology providers.
• Development of robotic-assisted, MRI-compatible, and automated biopsy guidance platforms will shape future market growth and innovation.

Frequently Asked Questions About the Biopsy Guidance System Market